Business · 09/06/2011Updated: 10/17/2026 · 1 min read

HHS Announces Final Effect of Designation of Employees for Special Exposure Cohort

Summary

The US Department of Health and Human Services (HHS) has made a final decision regarding the addition of employees from the Wah Chang facility in Albany, Oregon, to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000, a law aimed at providing compensation to workers exposed to hazardous materials.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Business Energy News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/17/2026

Proposed Data Collection Activity for Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey

The Administration for Children and Families, Department of Health and Human Services, is proposing to continue collecting data on diaper need and outcomes for beneficiaries of the Diaper Distribution Demonstration and Research Pilot, with proposed changes to the Beneficiary Survey and addition of an Organizational Survey.

Read summary →

Business · 9/16/2026

Agency Information Collection Request; 30-Day Public Comment Request

The Office of the Secretary (OS), Department of Health and Human Services, submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval, with a 30-day public comment period.

Read summary →

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/15/2026

National Cancer Institute Announces Closed Meeting

The National Cancer Institute has issued a notice regarding a closed meeting, which is not open to the public.

Read summary →

Business · 9/14/2026

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; Amended Notice of Meeting

The Office of the National Coordinator for Health Information Technology and the Health Information Technology Advisory Committee have issued an amended notice regarding a meeting, which appears to be a formal announcement of a scheduled event.

Read summary →